Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, Netherlands.
Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, Netherlands.
Lancet Gastroenterol Hepatol. 2019 Jan;4(1):20-31. doi: 10.1016/S2468-1253(18)30310-8. Epub 2018 Nov 23.
BACKGROUND: Hypnotherapy for irritable bowel syndrome (IBS) has been used primarily in patients with refractory symptoms in specialised departments and delivered on an individual basis. We aimed to test the hypothesis that hypnotherapy would be more effective than educational supportive therapy, and that group hypnotherapy would be non-inferior to individual hypnotherapy for patients with IBS referred from primary and secondary care. METHODS: We did a multicentre randomised controlled trial (IMAGINE) in 11 hospitals in the Netherlands. Patients with IBS, aged 18-65 years, who were referred from primary or secondary care were randomly allocated (3:3:1) in blocks of six using a computer-based random number table procedure by staff not involved in the treatment to receive six sessions of individual or group hypnotherapy or group educational supportive therapy (control group). The primary outcome was adequate relief of IBS symptoms, with responders defined as patients who reported adequate relief when asked once weekly on three or four occasions in 4 consecutive weeks. We compared hypnotherapy (both groups) with control in the intention-to-treat population (excluding individuals subsequently found to be ineligible for enrolment), and assessed non-inferiority of group hypnotherapy versus individual hypnotherapy in the per-protocol population (with a non-inferiority margin of 15%) at 3 months and 12 months. This trial is registered with ISRCTN, number ISRCTN22888906, and is completed. FINDINGS: Between May 31, 2011, and April 6, 2016, 494 patients referred for psychological treatment for IBS were assessed for eligibility, of whom 354 were randomly allocated to the three groups: 150 to individual hypnotherapy, 150 to group hypnotherapy, and 54 to educational supportive therapy. After exclusion of individuals subsequently found to be ineligible for enrolment, 142 patients in the individual hypnotherapy group, 146 in the group hypnotherapy group, and 54 in the control group were included in the intention-to-treat population. Of these, 22 (15%) patients in the individual hypnotherapy group, 22 (15%) in the group hypnotherapy group, and 11 (20%) in the control group dropped out before or during therapy. In the intention-to-treat analysis, the adequate response rate was 40·8% (95% CI 31·7-50·5) in the individual hypnotherapy group, 33·2% (24·3-43·5) in the group hypnotherapy group, and 16·7% (7·6-32·6) in the control group at 3 months. At 12 months, 40·8% (31·3-51·1) of patients in the individual hypnotherapy group, 49·5% (38·8-60·0) of patients in the group hypnotherapy group, and 22.6% (11·5-39·5) of patients in the control group reported adequate relief. Hypnotherapy was more effective than control at 3 months (odds ratio 2·9, 95% CI 1·2-7·4, p=0·0240) and 12 months (2·8, 1·2-6·7, p=0·0185). In the per-protocol analysis, 49·9% (39·2-60·6) in the individual hypnotherapy group and 42·7% (32·3-53·8) in the group hypnotherapy group had adequate relief at 3 months, and 55·5% (43·4-67·1) of individual and 51·7% (40·2-63·0) of group hypnotherapy patients reported adequate relief at 12 months. Group hypnotherapy was therefore non-inferior to individual hypnotherapy. Eight unexpected serious adverse reactions (six in the individual hypnotherapy group and two in the group hypnotherapy group) were reported, most of which were cancer or inflammatory bowel disease, and were judged by the medical ethics committee as not being related to the therapy. INTERPRETATION: Hypnotherapy should be considered as a possible treatment for patients with IBS in primary and secondary care. Furthermore, group therapy could allow many more patients to be treated for the same cost. FUNDING: None.
背景:针对难治性肠易激综合征(IBS)患者,在专门科室以个体为基础开展催眠疗法,疗效已得到证实。本研究旨在验证催眠疗法较教育支持疗法更有效,且对于从初级和二级保健转介而来的 IBS 患者,集体催眠疗法并不逊于个体催眠疗法。
方法:我们在荷兰 11 家医院开展了一项多中心随机对照试验(IMAGINE)。将年龄在 18-65 岁之间、由初级或二级保健转介而来的 IBS 患者,按 6 人一组的方式随机分组(3:3:1),使用基于计算机的随机数字表程序,由不参与治疗的工作人员进行分组,以接受个体或集体催眠疗法或集体教育支持疗法(对照组)6 次。主要结局是 IBS 症状得到充分缓解,通过在连续 4 周的 3 或 4 次随访中每周询问一次来评估缓解情况,充分缓解定义为患者报告缓解。我们在意向治疗人群(排除随后发现不符合入组条件的个体)中比较了催眠疗法(两组)与对照组的疗效,在方案人群(非劣效性边界为 15%)中比较了集体催眠疗法与个体催眠疗法的疗效,评估时间点为 3 个月和 12 个月。本试验在 ISRCTN 注册,编号 ISRCTN22888906,已完成。
结果:2011 年 5 月 31 日至 2016 年 4 月 6 日,对 494 名因 IBS 接受心理治疗的患者进行了评估,以确定其是否符合入组条件,其中 354 名患者被随机分配至三组:150 名接受个体催眠疗法,150 名接受集体催眠疗法,54 名接受教育支持疗法。排除随后发现不符合入组条件的个体后,142 名个体催眠疗法组患者、146 名集体催眠疗法组患者和 54 名对照组患者纳入意向治疗人群。其中,22 名(15%)个体催眠疗法组患者、22 名(15%)集体催眠疗法组患者和 11 名(20%)对照组患者在治疗前或治疗期间退出。意向治疗分析显示,个体催眠疗法组、集体催眠疗法组和对照组在 3 个月时的充分缓解率分别为 40.8%(95%CI 31.7-50.5)、33.2%(24.3-43.5)和 16.7%(7.6-32.6)。12 个月时,个体催眠疗法组、集体催眠疗法组和对照组分别有 40.8%(31.3-51.1)、49.5%(38.8-60.0)和 22.6%(11.5-39.5)的患者报告充分缓解。催眠疗法在 3 个月时(比值比 2.9,95%CI 1.2-7.4,p=0.0240)和 12 个月时(2.8,1.2-6.7,p=0.0185)的疗效均优于对照组。在方案人群分析中,个体催眠疗法组和集体催眠疗法组在 3 个月时的充分缓解率分别为 49.9%(39.2-60.6)和 42.7%(32.3-53.8),个体和集体催眠疗法组分别有 55.5%(43.4-67.1)和 51.7%(40.2-63.0)的患者在 12 个月时报告充分缓解。因此,集体催眠疗法并不逊于个体催眠疗法。报告了 8 例意外的严重不良事件(个体催眠疗法组 6 例,集体催眠疗法组 2 例),大多数为癌症或炎症性肠病,医学伦理委员会判定与治疗无关。
结论:催眠疗法应被视为初级和二级保健中 IBS 患者的一种可能治疗方法。此外,集体治疗可以以相同的成本治疗更多的患者。
资助:无。
Lancet Gastroenterol Hepatol. 2018-11-23
Cochrane Database Syst Rev. 2007-10-17
Aliment Pharmacol Ther. 2022-6
J Neurogastroenterol Motil. 2025-4-30
Front Neurosci. 2024-9-10
Front Psychol. 2024-6-3
Cureus. 2023-12-23
Front Med (Lausanne). 2023-2-22
NPJ Digit Med. 2023-3-10
Aliment Pharmacol Ther. 2022-6
Frontline Gastroenterol. 2020-11-23